Please be advised that Cytox Limited was placed into Liquidation on 4 January 2024, with Simon Farr and Anthony Collier of FRP Advisory Trading Limited being appointed Joint Liquidators of the Company. If you are owed money by Cytox Limited, or require further information about the Liquidation, please do not hesitate to contact cpmanchester@frpadvisory.com.
We are transforming the future of healthcare by predicting those most at genetic risk for developing late-onset Alzheimer’s disease
Cytox’s polygenic risk scoring approaches help pharmaceutical and biotech companies cost-effectively and accurately stratify candidates for clinical trials
Services include genetic risk assessment for amyloid status and cognitive decline, as well as mTOR-associated pathway analysis profiling for more accurate drug targeting
We are transforming the future of healthcare by predicting those most at genetic risk for developing late-onset Alzheimer’s disease
Cytox’s polygenic risk scoring approaches help pharmaceutical and biotech companies cost-effectively and accurately stratify candidates for clinical trials
Services include genetic risk assessment for amyloid status and cognitive decline, as well as mTOR-associated pathway analysis profiling for more accurate drug targeting
LATEST NEWS
Jul 10, 2023
Cytox CEO, Dr. Richard Pither, Talks About genoSCORE™-ACT Genetic Risk Test for Alzheimer's Disease on the UK's Only Dementia-Focussed Radio Show – ‘The 'D' Word With Pete Hill'